Immutep Announces Promising New Clinical Data From Triple Combination Therapy in INSIGHT-003 Trial

Immutep, Ltd. announced new encouraging clinical data in first line NSCLC from INSIGHT-003, an investigator-initiated Phase I trial conducted by the Frankfurt Institute of Clinical Cancer Research IKF.